ACIP review of the hepatitis B birth dose vaccination remains a grave concern - Please read more here.

Site Search

You searched for "hepatitis D"

  • Hepatitis B and Injection Drug Use: Risks, Barriers to Care, and Prevention Strategies

                      Hepatitis B is a liver infection which is caused by the hepatitis B Virus (HBV). Hepatitis B is transmitted from person to person through blood, semen, or other bodily fluids. You can learn more about the ways hepatitis B is spread here. People who inject drugs (PWID) are at high risk for contracting the virus due to the sharing of needles and low  awareness and education about hepatitis B. HBV Prevalence among PWID Communities People who inject drugs (PWID) are at high risk for hepatitis B virus infection due to various factors, including sharing injection equipment and lack of awareness about hepatitis B transmission. Using unclean needles to inject drugs can result in the exchange of blood. This increases a person’s risk of being exposed to the virus. Hepatitis B prevalence among PWID is much higher than in the general population. Chronic HBV infection has been identified in 3.5% to 20.0% of PWID in a variety of settings, and 22.6% of PWID have evidence of past infection (Haber & Schillie, 2021). Drug injection is the most common risk for persons ages 18-40 years old with hepatitis B virus.  Barriers to Care for PWID Communities Access to treatment can be a significant barrier for PWID, who may face stigma and discrimination in healthcare settings. To find out if someone has hepatitis B it is recommended that a triple panel hepatitis B test be run (which includes HBsAg, HBcAb and HBsAb). These tests will help identify people with hepatitis B, a previous exposure to hepatitis B and those who have protection against hepatitis B infection (through vaccination). For those with hepatitis B, treatment options for hepatitis B consist of antiviral medications that can help to control the virus and reduce the risk of serious liver damage, cirrhosis, and liver cancer. Treatment is taken daily for life generally. PWID lack access to these treatments due to the stigma attached with substance use and

    http://www.hepb.org/blog/hepatitis-b-injection-drug-use-risks-barriers-care-prevention-strategies/
  • If it's not broken, don't fix it! A hepatitis B vignette.

    The Scenario Yufei Zhao is 45 years old and lives with his family in Philadelphia,   Pa. Yufei discovered that he had hepatitis B when he attended a community health fair with his family. Even though he was instructed to talk about his diagnosis with a doctor and learn more about possible treatment options, Yufei decided to do nothing as he did not feel sick. While he has health insurance through his employer, he never utilizes any health care services. He often skips annual wellness visits as he says he “never gets sick.”   A few weeks ago, Yufei’s family noticed that he has been skipping meals frequently saying he’s full or not hungry. At his daughter’s urging, he decided to go for a visit. After conducting some more tests, his doctor explained that the chronic infection with the hepatitis B virus had progressed substantially, and he had developed cirrhosis. After an MRI diagnosis, it was revealed that Yufei had liver cancer. The Hepatologist (liver doctor) explained to Yufei that the liver is an important organ and acts as a cleaning system for the body. It removes toxic waste, purifies blood, and helps to digest food properly. When the virus entered the liver, it made many copies of itself and started attacking healthy liver cells. This led to inflammation and weakened the ability of the liver to carry out its most essential tasks. Because he was never monitored for hepatitis B, the virus allowed tumors to grow in the liver which caused the cancer. When the tumors grow in size or number, it eventually spreads to other parts of the body and disrupts other vital processes as well.  The doctor mentioned that liver cancer is often called the silent disease because symptoms may not always be present. Even with a hepatitis B, a person could look or feel okay but that does not mean the virus isn’t active and causing damage. When the symptoms do show up, it might be too late to prevent liver cancer. After discussing his options with the doctor, Yufei

    http://www.hepb.org/blog/not-broken-dont-fix-hepatitis-b-vignette/
  • Ignore it till it goes away! A hepatitis B vignette.

    The Scenario: Aroha Kawai just started a new job as a medical interpreter for Pacific Islander patients diagnosed with COVID-19. As a critical source of communication for the providers and the patients, she is often called to work night and weekend shifts. Aroha had a difficult conversation with the family members of a critical COVID-19 patient on whether they should discontinue ventilation support for the ailing grandmother. During this time, Aroha’s family noticed changes in her behavior. She stopped eating regularly, lost weight and repeatedly cancelled plans to go out. Aroha dismissed her family's concerns as physical manifestations of the emotional burnout from work. Recently she attended a health fair hosted by her department at work. She approached a viral hepatitis screening booth and decided to get tested for hepatitis B. The following week, she received her results in the mail. Her results indicated that she had tested positive for hepatitis B. She shared her diagnosis with her mother who informed her that her grandfather died from liver cancer.   Aroha then followed up with her primary care doctor.  She discovered that she had chronic hepatitis B. Even though the ultrasound did not show any evidence of cirrhosis, her doctor ordered an imaging test (U/S, CT, MRI) to screen for liver cancer. Unfortunately, Aroha was diagnosed with early-stage liver cancer.   Fortunately, the cancer had not spread and did not infect nearby blood vessels. Her doctor suggested a partial hepatectomy to remove the tumor safely as the rest of the liver was still healthy. Aroha decided to adhere to her doctor’s advice and successfully underwent the surgery. She has taken some time off from work to focus on recuperating from the surgery and spending time with loved ones.       The Challenge: Dismissal of Symptoms: Aroha initially ignored the physical symptoms of liver cancer. It is true that signs and symptoms may not necessarily be present. However, it

    http://www.hepb.org/blog/ignore-till-goes-away-hepatitis-b-vignette/
  • CHIPO Partner Highlight: Great Lakes Peace Centre

     The Coalition Against Hepatitis for People of African Origin (CHIPO) is a national community coalition that is co-founded and led by the Hepatitis B Foundation, comprised of organizations and individuals who are interested in addressing the high rates of hepatitis B infection among African communities in the US. Recently, CHIPO has started to expand its reach to communities in Africa and has welcomed new partners from the Continent. This month, in honor of Minority Health Month, we highlight a partnership between CHIPO and Great Lakes Peace Centre (GLPC) in Kasese, Uganda. CHIPO has recently provided GLPC with educational resources that are tailored for African communities, which GLPC is translating into local dialects and will use in a strategy to raise awareness and provide education about hepatitis B, primarily to rural women and youth in Kasese District. A recent interview with Bwambale Arafat, Head of Health and Policy Officer at GLPC, sheds light on some of the significant barriers that impede hepatitis B screening, prevention, and care in Uganda (and much of the African continent) and showcases some of the extraordinary work of GLPC on a host of issues, of which viral hepatitis is just one.  CHIPO: Can you share a little bit about yourself? What is your connection to hepatitis? Arafat: I work with the Great Lakes Peace Centre, which is a grassroots, youth-led organization, here in Kasese District, a rural area in Rwenzori region, western Uganda (near the border of the Democratic Republic of Congo, about 400 kilometers from the capital city of Kampala). Most of our work with hepatitis B is focused on raising awareness and providing education about the virus to women and youth in the area, who are the most important people to reach. We also engage in a lot of advocacy initiatives, as well as efforts to lower stigma and discrimination. My personal connection to hepatitis B is the diagnosis of my uncle with hepatitis B and liver cancer and his death shortly

    http://www.hepb.org/blog/chipo-partner-highlight/
  • CHIPO Is Looking for New Members!

    By Beatrice Zovich           Are you a member of the African diaspora in the United States? Do you work for an organization that serves these communities? We would love for you to join CHIPO - the Coalition Against Hepatitis for People of African Origin! CHIPO is a national community coalition, co-founded and led by the Hepatitis B Foundation. Our members include a variety of individuals and organizations from all over the country, who are interested in and focused on addressing the high rates of hepatitis B among African communities in the US., which are disproportionately affected by hepatitis B and liver cancer. In some parts of the country, rates of chronic hepatitis B infection in African communities are estimated to range between 5 and 15% of people.  The purpose of CHIPO is to provide a space for an open exchange of ideas, best practices, and  information about how to dismantle some of the many barriers that stand in the way of preventing, diagnosing, and treating chronic hepatitis B infection, and preventing liver cancer, in African immigrant communities. These barriers include a lack of disease awareness, high rates of stigma, limited access to healthcare and services, and the silent nature of the disease, which often does not present any symptoms until significant liver damage has occurred - a process which could take years or even decades. As a result, most African community members who have hepatitis B DO NOT KNOW that they are infected. This puts them at much greater risk for premature death from cirrhosis or liver cancer. CHIPO, meaning “gift” in the Shona language, aims to disseminate accurate information about hepatitis B transmission, prevention, and treatment among community members, healthcare providers, and organizational leaders, and to improve the national capacity to raise hepatitis B awareness, testing, vaccination, and linkage to care among highly affected African communities. CHIPO also works to ensure that

    http://www.hepb.org/blog/chipo-looking-new-members/
  • Marshallese

    Ruwainene tok nan Kajin Majol Jebta eo ikijen Ejaak in Webjait eo kin Hepatitis B Hepatitis B ej kwalok ke ej juon kij ejab jedmatmat, im elon armej rejab jela ke reboke. Webjait in eped melele ko kin waween boprae, kakolkol lale im keplaak hepatitis B. Kemij rejan iok nan kajeded melele kein ipen ro jeram, baamle im ro jet ilo jukjuk in bed eo am. Jet kein waween raorok nan kememej ikijen hepatitis B: Hepatitis B ejab itok jen bodan – ej walok jen juon kij.  Ewor juon wa eo etiljok eo enaj kejbarok iok jen hepatitis B nan indeo.  Ewor juon kakolkol nan bok botoktok eo emlak nan kakilen naninmej in hepatitis B.  Ewor jekjek ko nan komadmod. Hepatitis B ej juon Naninmej eo Ebedjake Aolepen Lal Hepatitis B emaron jelet jabrewot armej jabrewot iio ak rilal, ijoke armej ro jen kajojo jikin ko hepatitis B eka an walok, einwot Ejia, motan ko ilo Abrika im Turok in Amedka, Turear in Iorob, im Iolab Rear, rej ijoko elab an kawotata ilo aer bok naninmej in. Hepatitis B ej bar lab an walok ipen ri Amedka ro rekar lotak (ak ro jineer jemeer rekar lotak) ilo jikin kein. Ewor jubwiki in milion jonan armej ilo lalin ro ewor aer hepatitis B. Elon armej rejab lukin jela ke reboke, im ejelok kein kakolkol ko – ijoke ewor waween ko raorok koj aikwij in jela. Bok kakolkol ko kin hepatitis B emaron kejbarok mour eo am. Elane kojela bwe ewor am hepatitis B, komaron koman kelet ko nan ejmour eo am bwe deka in jibuke eo am en ejmourur im komaron lolok juon takto eo enaj jipan iok jela kilen kejbarok im boprae jen an joreen aj eo. Hepatitis B Foundation ej juon doulul ilo kien jaab nan worlok nan wot bukot juon jekjek eo najnkemour im lonaj lonlok mour an ro hepatitis B ejelet er ipelaak in lal iloan ekatak ko, jelelokijen im naan in kokjoor nan rinaninmej. Riketak: Melele ko reped ilo wepjait in rej nan un ko katakin wot. Hepatitis B Foundation eo ejab juon doulul nan takto. Jouj im kenono ipen takto eo am ak juon eo etijemlok ilo lelok ejmour nan jipan kejbarok im kokabiloklok. Welcome to the Marshallese Chapter of the Hepatitis B Foundation Website Hepatitis B is known as a silent disease, and most people don’t even know they are infected. This website contains information about preventing, diagnosing and managing hepatitis B. We encourage you to share this information with your friends, family and others in your community. Here are some important things to remember about hepatitis B: Hepatitis B is not inherited - it is caused by a virus.  There is a safe vaccine which will protect you from hepatitis B for life.  There is a simple blood test to diagnose hepatitis B.  There are treatment options. Hepatitis B is a Global Disease Hepatitis B can infect any person of any age or ethnicity, but people from parts of the world where hepatitis B is common, such as Asia, parts of Africa and South America, Eastern Europe, and the Middle East, are at much higher risk for getting infected. Hepatitis B is also common among Americans who were born (or whose parents were born) in these regions. There are hundreds of millions of people worldwide who have hepatitis B. Most people don’t even know they are infected, and don’t have symptoms – but there are many important things you should know. Getting tested for hepatitis B can save your life. If you know you have hepatitis B, you can make lifestyle choices to keep your liver healthy and you can see a doctor to help manage the virus and prevent liver damage. The Hepatitis B Foundation is a national nonprofit organization dedicated to finding a cure and helping to improve the quality of life for all those affected by hepatitis B worldwide through research, education and patient advocacy. Disclaimer: The information that is provided on this website is for educational purposes only. The Hepatitis B Foundation is not a medical organization. Please talk to your doctor or a qualified health care provider for personal medical care and advice. 

    https://www.hepb.org/languages/marshallese/
  • Resources for Educators

    These resources are part of the Centers for Disease Control and Prevention's Know Hepatitis B campaign to raise awareness about and promote testing for hepatitis B in high-risk communities in the U.S. These materials are the result of a collaboration between CDC, Hepatitis B Foundation, and CHIPO partners, and were pilot tested in the community to ensure cultural and content relevancy. We encourage you to download, print and share these resources widely! If you would like to request that any already printed materials be shipped to you, free of charge, please complete this form. For questions and support, email info@hepb.org.  Training and Community Resources Hepatitis B Presentation for Community Health Workers Hepatitis B Flipchart for Community Health Education (CDC's Product of the Month April 2020!) Hepatitis B Resources for Communities in East Africa Fact Sheets and Printable Resources Locating Hepatitis B Testing Resources Using the Hepatitis B Flipchart for Community Education Printable Hepatitis B Takeaway Card (English) Printable Hepatitis B Takeaway Card (French) Printable Hepatitis B Takeaway Card (Swahili) Printable Hepatitis B Takeaway Card (Amharic) Printable Hepatitis B Takeaway Card (Arabic) #JustB Hepatitis B African Storyteller Videos Bright's Hepatitis B Story (Ghanaian Storyteller) [embed width="309" height="175" class="leftAlone" thumbnail="https://i.ytimg.com/vi/9xhSvLR0x-s/hqdefault.jpg?r"]http://www.youtube.com/watch?v=9xhSvLR0x-s&feature=emb_imp_woyt[/embed] Youtube - English       Youtube - Twi William's Hepatitis B Story (Ghanaian Storyteller) [embed width="321" height="181" class="leftAlone" thumbnail="https://i.ytimg.com/vi/iphhwnShMpU/hqdefault.jpg?r"]http://www.youtube.com/watch?v=iphhwnShMpU&feature=emb_imp_woyt[/embed] Youtube - English Adama's Hepatitis B Story (Senegalese Storyteller) [embed width="325" height="244" class="leftAlone" thumbnail="https://i.ytimg.com/vi/AQMqsmijvgo/hqdefault.jpg?r"]http://www.youtube.com/watch?v=AQMqsmijvgo&t=3s[/embed] YouTube - English     YouTube - French     YouTube - Mandingo Ismail's Hepatitis B Story (Nigerian Storyteller) [embed width="326" height="184" class="leftAlone" thumbnail="https://i.ytimg.com/vi/z6LB3cmEsyk/hqdefault.jpg?r"]http://www.youtube.com/watch?v=z6LB3cmEsyk[/embed] YouTube - English Gold's Hepatitis B Story (Nigerian Storyteller) [embed width="319" height="180" class="leftAlone" thumbnail="https://i.ytimg.com/vi/UiT8yUyqGjw/hqdefault.jpg?r"]http://www.youtube.com/watch?v=UiT8yUyqGjw[/embed] YouTube - English Bunmi's Hepatitis B Story (Nigerian Storyteller) [embed width="323" height="182" class="leftAlone" thumbnail="https://i.ytimg.com/vi/GQ1zzQwwmmM/hqdefault.jpg?r"]http://www.youtube.com/watch?v=GQ1zzQwwmmM[/embed] Youtube - English FK's Hepatitis B Story (Storyteller from Burkina Faso) [embed width="323" height="182" class="leftAlone" thumbnail="https://i.ytimg.com/vi/Hz6xFNtIKdE/hqdefault.jpg?r"]http://www.youtube.com/watch?v=Hz6xFNtIKdE&feature=emb_imp_woyt[/embed] YouTube - English      YouTube - French Sonia's Hepatitis B Story (Nigerian Storyteller) [embed width="323" height="182" class="leftAlone" thumbnail="https://i.ytimg.com/vi/Kd22voWXwGk/hqdefault.jpg?r"]http://www.youtube.com/watch?v=Kd22voWXwGk[/embed] YouTube - English John's Hepatitis B Story (Nigerian Storyteller) [embed width="320" height="181" class="leftAlone" thumbnail="https://i.ytimg.com/vi/7Zj6SQYXmUk/hqdefault.jpg?r"]http://www.youtube.com/watch?v=7Zj6SQYXmUk[/embed] YouTube - English Dayo's Hepatitis B Story (Nigerian Storyteller) [embed width="323" height="182" class="leftAlone" thumbnail="https://i.ytimg.com/vi/Jb0eqyeVDcQ/hqdefault.jpg?r"]http://www.youtube.com/watch?v=Jb0eqyeVDcQ[/embed] YouTube - English

    https://www.hepb.org/research-and-programs/chipo/resources/resources-for-educators/
  • Funding Opportunities

    Several new opportunities for funding of hepatitis B and liver cancer/ hepatocellular carcinoma (HCC) research are currently available.  Below you will find summaries of recently announced opportunities from the United States (US) National Institutes of Health (NIH).   Note that the NIH can only support grants for HBV and HCC research if people submit them.  To address this obstacle, we are encouraging them to establish dedicated funding for HBV and HCC to stimulate more applications.  We encourage researchers to pass this information to colleagues, submit your own applications, and help with advocacy for HBV and HCC whenever possible.  It is also important to note that most NIH grants can involve or be from non-US sources.  Check eligibility requirements.   Please be sure to review the key dates, especially the expiration date as some of these announcements are set to renew.   *UPCOMING SBIR Contract in FY2020- Antiviral Drugs To Cure Chronic Hepatitis B Virus Infection. NIAID topic for NIH SBIR contract solicitation. https://www.niaid.nih.gov/grants-contracts/january-2019-dmid-council-approved-concepts?utm_campaign=+36681533&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term=   *NIH/NIAID- Research to Advance HBV Cure: HIV/HBV Co-Infection and HBV Mono-Infection (RO1 Clinical Trial Not Allowed: The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative basic, translational, and clinical research to identify and address the challenges to achieving hepatitis B virus (HBV) cure in the presence or absence of human immunodeficiency virus (HIV). https://grants.nih.gov/grants/guide/pa-files/PAS-19-097.html   *NIH/NIAID- HIV and Hepatitis B Co-Infection: Advancing HBV Functional Cure through Clinical Research (R21): The purpose of this Funding Opportunity Announcement (FOA) is to fill scientific gaps needed to (a) inform HBV functional cure strategies by furthering our understanding of unique challenges impacting HBV and HIV co-infected hosts and (b) advance the discovery and development of novel HBV interventions that are safe and achieve a functional cure in HIV and HBV co-infected individuals. https://grants.nih.gov/grants/guide/pa-files/pa-17-278.html   *NIH/NCI- Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 and R01 - Clinical Trial Not Allowed):The purpose of this concept initiative is to promote etiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States. https://grants.nih.gov/grants/guide/pa-files/pa-18-677.html   NIH/NIDA/NIAAA- Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34 Clinical Trial Optional): This Funding Opportunity Announcement (FOA) for R34 applications seeks to support: (a) pilot and/or feasibility testing of innovative new, revised, or adapted prevention intervention approaches to prevent or delay the initiation and onset of drug and alcohol use, the progression to misuse or problem use or alcohol and other substance use disorder, reduce drinking and driving and deaths related to impaired driving, and the drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis  among diverse populations and settings; and, (b) pre-trial feasibility and acceptability testing for prevention services and systems research. It is expected that research conducted via this R34 mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale drug or alcohol abuse prevention and/or drug- or alcohol-related HIV prevention intervention studies. This R34 FOA does not support applications for which the sole focus is development of intervention protocols, manuals, or the standardization of protocols. Any intervention development work must be embedded within a pilot/feasibility study. Of particular interest is prevention research that addresses current public health priorities and priority settings and systems. https://grants.nih.gov/grants/guide/pa-files/pa-18-775.html   NIH/-NICHD- Advancing Understanding, Prevention, and Management of Infections Transmitted from Women to their Infants (R01 Clinical Trial Optional): The purpose of this funding opportunity announcement (FOA) is to stimulate investigations including translational, epidemiologic and clinical studies and trials that improve the understanding, prevention and clinical outcomes of non-HIV infections transmitted from women to their offspring during pregnancy, labor and delivery, and breastfeeding. NICHD is committed to supporting research that will increase scientific understanding of and treatments for high-priority perinatal infections. https://grants.nih.gov/grants/guide/pa-files/PA-18-031.html   *NIH/NIMHD/NIAAA/NCI- Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R21)- The purpose of the initiative is to support multidisciplinary innovative exploratory and developmental research to understand the underlying etiologic factors and the mechanisms that result in disparities in chronic liver diseases and cancer in the US. This FOA utilizes the Research Project Grant (R21) mechanism, and is suitable for early phase, pilot, or exploratory/developmental projects.  Investigators who are interested in proposing larger scale, later phase projects based upon substantial preliminary data should submit applications to the companion FOA PAR-17-151 of identical scientific scope which uses the NIH (R01) grant mechanism.  https://grants.nih.gov/grants/guide/pa-files/PAR-17-150.html  

    https://www.hepb.org/research-and-programs/research-for-a-cure/research-funding-opportunities/

  • Maligayang Pagdating sa Tagalog na Kabanata ng Hepatitis B Foundation Website Ang hepatitis B ay kilala bilang isang tahimik na sakit, at karamihan sa mga tao ay hindi alam na sila ay nahawahan. Ang website na ito ay naglalaman ng impormasyon tungkol sa pagpigil, pagsuri at pangangasiwa ng hepatitis B. Hinihimok ka namin na ibahagi ang impormasyong ito sa iyong mga kaibigan, pamilya at iba pa sa inyong komunidad. Narito ang ilang mahahalagang bagay na dapat tandaan tungkol sa hepatitis B: Ang hepatitis B ay hindi namamana – ito ay sanhi ng virus. 
 Mayroong ligtas na bakuna na magpoprotekta sa iyo mula sa hepatitis B nang panghabang buhay. 
 Mayroong simpleng pagsusuri sa dugo upang matukoy ang hepatitis B. 
 Mayroong mga opsyon sa paggagamot. Ang hepatitis B ay Isang Pandaigdigang SakitMaaaring mahawa ng hepatitis B ang sinumang tao sa anumang edad o etnisidad, ngunit ang mga tao mula sa mga bahagi ng mundo kung saan karaniwan ang hepatitis B, tulad ng Asya, mga bahagi ng Aprika at Timog Amerika, Silangang Europa, at Gitnang Silangan, ay may mas mataas na panganib na mahawahan. Karaniwan din ang hepatitis B sa mga Amerikanong ipinanganak (o ang mga magulang ay ipinanganak) sa mga rehiyong ito. Daan-daang milyong tao sa buong mundo ang may hepatitis B. Karamihan sa mga tao ay hindi alam na sila ay nahawahan, at walang mga sintomas – ngunit maraming mahahalagang bagay ang dapat mong malaman. Ang pagpapasuri para sa hepatitis B ay makakapagligtas ng iyong buhay. Kung alam mong mayroon kang hepatitis B, maaari kang gumawa ng mga pasya sa pamumuhay upang mapanatiling malusog ang iyong atay at maaari ka ring magpatingin sa doktor upang matulungang pangasiwaan ang virus at maiwasan ang pinsala sa atay. Ang Hepatitis B Foundation ay isang pambansang hindi-pangkalakal na organisasyon na nakatuon sa paghahanap ng lunas at tumutulong na mapabuti ang kalidad ng buhay para sa lahat na apektado ng hepatitis B sa buong mundo sa pamamagitan ng pananaliksik, edukasyon at pagtataguyod ng pasyente. Pagtatatwa: Ang impormasyong ibinigay sa website na ito ay para sa mga layuning pang-edukasyon lamang. Ang Hepatitis B Foundation ay hindi isang medikal na organisasyon. Mangyaring kausapin ang iyong doktor o ang isang k’walipikadong tagapagbigay ng pangangalagang pangkalusugan para sa personal na medikal na pangangalaga at payo. Welcome to the Tagalog Chapter of the Hepatitis B Foundation Website Hepatitis B is known as a silent disease, and most people don’t even know they are infected. This website contains information about preventing, diagnosing and managing hepatitis B. We encourage you to share this information with your friends, family and others in your community. Here are some important things to remember about hepatitis B: Hepatitis B is not inherited - it is caused by a virus. 
 There is a safe vaccine which will protect you from hepatitis B for life. 
 There is a simple blood test to diagnose hepatitis B. 
 There are treatment options. Hepatitis B is a Global DiseaseHepatitis B can infect any person of any age or ethnicity, but people from parts of the world where hepatitis B is common, such as Asia, parts of Africa and South America, Eastern Europe, and the Middle East, are at much higher risk for getting infected. Hepatitis B is also common among Americans who were born (or whose parents were born) in these regions. There are hundreds of millions of people worldwide who have hepatitis B. Most people don’t even know they are infected, and don’t have symptoms – but there are many important things you should know. Getting tested for hepatitis B can save your life. If you know you have hepatitis B, you can make lifestyle choices to keep your liver healthy and you can see a doctor to help manage the virus and prevent liver damage. The Hepatitis B Foundation is a national nonprofit organization dedicated to finding a cure and helping to improve the quality of life for all those affected by hepatitis B worldwide through research, education and patient advocacy. Disclaimer: The information that is provided on this website is for educational purposes only. The Hepatitis B Foundation is not a medical organization. Please talk to your doctor or a qualified health care provider for personal medical care and advice.

    https://www.hepb.org/languages/tagalog/
  • Hepatitis B Foundation Mourns the Loss of Pioneering Hepatitis B Physician-Scientist Dr. W. Thomas London

    Dr. London was Long-time Board Member, Medical Advisor, and Mentor DOYLESTOWN, PA (June 3, 2017): W. Thomas London, MD, an internationally renowned physician-scientist dedicated to the study of hepatitis B, passed away June 3 at the age of 85. Dr. London was a key member of the research team that discovered the hepatitis B virus in the early 1960s, and longtime member of the Board of the Hepatitis B Foundation and its research arm, the Baruch S. Blumberg Institute, where he also served as a distinguished scientific and medical advisor. Dr. London represented the very best in a doctor and scientist - sincere compassion, and successful achievement in advancing the cause and cure of hepatitis B. His wisdom and guidance will be greatly missed.  “This is a terrible loss. Tom London was not only one of the finest medical and scientific minds, but a gracious, caring doctor, who always had time for patients and fellows, no matter how busy he was," said Timothy Block, PhD, President, Hepatitis B Foundation and its Blumberg Institute. “He was a role model, and an inspiration for me, and for a generation. One of a kind.”  In the 1966, Dr. London left his position at the National Institute of Health (NIH) to work with Dr. Baruch S. Blumberg at the Fox Chase Cancer Center in Philadelphia. Dr. London and colleagues made the first correlation between a then newly identified virus and hepatitis, a serious infection of the liver. Dr. Blumberg went on to receive the Nobel Prize for the discovery of the new hepatitis B virus, but always acknowledged the critical role of Dr. London in linking the new virus to a clinical disease known as “hepatitis” or serious liver inflammation. Dr. London remained at Fox Chase where his research contributed to linking the hepatitis B  virus to primary liver cancer, and continued to work on epidemiologic studies and large community-based screening and vaccination programs in the Philadelphia area, Haimen City, China, and Senegal, West Africa. Those programs have become models of public health outreach in the effort to prevent and control an infectious disease like hepatitis B. In 2009, Dr. London retired from Fox Chase as a Senior Member, after which he volunteered his professional time working with the public health professionals at the Hepatitis B Foundation and research scientists at the Blumberg Institute, both headquartered in Doylestown, PA. He devoted his entire career to research on the etiology, pathogenesis, and prevention of primary liver cancer (or hepatocellular carcinoma, HCC) with particular emphasis on the epidemiology of chronic hepatitis B infection. In 2015, to recognize the extraordinary contributions of Dr. London, the Blumberg Institute created the W. Thomas London Distinguished Professorship.  At the ceremony to celebrate the named professorship, Harvey Alter, MD, eminent scientist at the NIH and co-discoverer of the hepatitis B virus (and C virus), described the seminal contributions of Dr. London as "world changing in magnitude, but done quietly, and modestly." “Dr. London inspired my career in infectious disease,” says Nathaniel Brown, MD, infectious disease physician, retired pharmaceutical executive focused on hepatitis B drug development, and Board Member of the Hepatitis B Foundation. "This is a great loss for the hepatitis B community." Dr. London is a graduate of Oberlin College and Cornell University Medical College. He received his clinical training in Internal Medicine at Bellevue Hospital and the Memorial Sloan-Kettering Cancer Center in New York City. His work has resulted in more than 285 publications, election as a Fellow of the American Association for the Advancement of Science, editor of prestigious peer-reviewed cancer journals, and many awards. He was a resident of Wyncote, PA, and is survived by his wife Linda, with whom he just celebrated 60 years of marriage, and their 4 daughters and 8 grandchildren. Relatives and friends are invited to memorial services on Thursday, June 8 at 2:00 pm at Goldsteins’ Rosenberg’s Raphael Sacks, 6410 N. Broad Street, Philadelphia, PA 19126. Immediately following services, the family will host a reception. Contributions in his memory may be made to the Hepatitis B Foundation, 3805 Old Easton Road, Doylestown, PA 18902, www.hepb.org, or to the Cheltenham Township Adult School, 500 Rices Mill Road, Wyncote, PA 19095, www.cheltenhamtownshipadultschool.org       About the Hepatitis B Foundation: The Hepatitis B Foundation is the nation’s leading nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. To learn more, go to www.hepb.org, read our blog at http://hepb.org/blog, follow us on Twitter @HepBFoundation, find us on Facebook at www.facebook.com/hepbfoundation or call 215-489-4900. About the Baruch S. Blumberg Institute: The Baruch S. Blumberg Institute is an independent, nonprofit research institute established in 2003 by the Hepatitis B Foundation to fulfill its research mission and to conduct discovery research and nurture translational biotechnology in an environment conducive to interaction, collaboration and focus. It was renamed in 2013 to honor Baruch S. Blumberg, who won the Nobel Prize for his discovery of the hepatitis B virus and co-founded the Hepatitis B Foundation. To learn more, visit www.blumberginstitute.org. # # #

    https://www.hepb.org/news-and-events/news-2/london/